Clinical trial
Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
NCT00421109 · Faes Farma, S.A., Industry · Completed
Key facts
| NCT number | NCT00421109 |
|---|---|
| Title | Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria |
| Official title | Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria |
| Lead sponsor | Faes Farma, S.A., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Urticaria |
| Intervention type | Drug |
| Interventions | Bilastine, Levocetirizine, Placebo |
| Enrollment | 522 |
| Start date | Jul 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Jan 11, 2007 |
| Last update posted | Apr 5, 2012 |
| Countries | Argentina, Belgium, France, Germany, Poland, Romania, Spain |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: